AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 51 min read$ALMS

Bradley Mark Christopher sold $68K of ALMS

Bradley Mark Christopher (Chief Development Officer) sold 2,572 shares of ALUMIS INC. (ALMS) at $26.37 on 2026-08-03.

Original reporting
SEC EDGAR · Bradley Mark Christopher
Published Aug 5, 2026, 10:21 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 11:02 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ALMS
Neutral
low confidence
Mentioned
$ALMS
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALMSNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details by the named officer, including price, shares, and post-transaction holdings.

02

Market read

Traders may note insider selling, but the filing alone is usually not a standalone catalyst for repricing.

03

What to watch

The article does not provide context for the sale (taxes, scheduled liquidity needs, or prior grants), so interpreting it as a strong signal is risky.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-05 after-hours; transaction dated 2026-08-03

Background

The article is a SEC Form 4 insider transaction disclosure for ALUMIS INC. (ALMS).

Company-level read

Ticker impact

$ALMSNeutralLow confidence
Context

ALMS disclosed an insider open-market sale by its Chief Development Officer of 2,572 shares at $26.37 on 2026-08-03.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven and typically fades unless accompanied by other company-specific news.

Evidence & confidence

The filing provides transaction size, price, and post-sale holdings, but no accompanying guidance, operational update, or enforcement/regulatory action.

Market effects

Sector

Minimal, as this is company-specific insider trading with no sector-wide signal.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be planned for liquidity or diversification; the absence of a stated 10b5-1 plan does not automatically imply bearish information.

Key entities

  • issuer
    ALUMIS INC.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Bradley Mark Christopher

    Chief Development Officer who sold 2,572 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ALMS insider trading history →

Related articles

SEP 1
$ALMSMedAI 8/10

Alumis Phase 2b LUMUS Trial Misses Endpoints; Stock Plunges

Alumis Inc. (ALMS) reported Phase 2b LUMUS trial results for Envudeucitinib in SLE, missing primary and secondary endpoints overall but showing promise in a subset of patients with high interferon gene signature. The drug demonstrated improvements in several measures in this subgroup and was well tolerated. The company plans to discuss Phase 3 development with regulators. ALMS stock fell over 55% in pre-market trading.

rttnews.com2 min
SEP 1
$ALMSHighAI 8/10

Why is Alumis stock collapsing today?

Alumis stock fell 54.2% in pre-market trading after its Phase 2b LUMUS trial for envudeucitinib in systemic lupus erythematosus missed primary and secondary endpoints. A subgroup of patients showed positive responses, but the overall trial population was under-represented. The company plans to discuss a Phase 3 program with regulators. The Nasdaq, S&P 500, and Dow Jones also declined, exacerbating the sell-off.

investing.com2 min
SEP 1
$ALMSHighAI 8/10

Alumis stock tumbles 55% after lupus drug trial misses goals

Alumis Inc. (ALMS) shares dropped 55% after its Phase 2b LUMUS trial for envudeucitinib in lupus failed primary and secondary endpoints. The trial enrolled 408 patients but showed improvements only in a subgroup with high interferon gene signature (IFNGS-high). The drug was well-tolerated, and the company plans to discuss Phase 3 development for this subgroup with regulators. Alumis remains on track to submit a New Drug Application for psoriasis in Q4 2026.

investing.com2 min
SEP 1
$ALMSLowAI 8/10

Alumis Inc.: Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)

Alumis Inc. (ALMS) reported that its Phase 2b LUMUS trial of envudeucitinib for systemic lupus erythematosus (SLE) did not meet primary and secondary endpoints in the overall population. However, a prespecified subgroup of patients with high interferon gene signature (IFNGS-high) showed robust responses. The company plans to discuss Phase 3 development with regulators. Envudeucitinib was well tolerated. Alumis remains on track to submit an NDA for envudeucitinib in moderate-to-severe plaque psor

finanznachrichten.de2 min